Oxford Biomedica......the next level !!!!

Eurofox, Alizyme expect to out-license three drugs during 2004 (COLAL-PRED, ATL-962 and Renzapride) and one during 2005 (ATL-104). Three of AZM's drugs have completed PIIb and one is in PIIa. Conversely, Oxford Biomedica (if very lucky) may out-license Trovax around the end of 2004 or in H1 2005 (12 to 18 months from now) imo. The rest of OXB's pipeline looks early stage or pre-clinical, and all is high-risk. Alizyme is the better short-term investment of the two imo. Incidentally, Framlington have just increased their stake in AZM.